NRG1基因融合非小细胞肺癌的发病机制、临床特点及治疗策略研究进展  

Research progress on molecular mechanisms,clinical features,and treatment methods of NRG1 gene fusion NSCLC

作　　者：任腾丽 郭媛 史展雨 王晚萍[1,2] REN Tengli;GUO Yuan;SHI Zhanyu;WANG Wanping(Graduate School,Shanxi Medical University,Taiyuan 030000,China;不详)

机构地区：[1]山西医科大学研究生院,山西太原030000 [2]长治市人民医院呼吸与危重症医学科,山西长治046000

出　　处：《山东医药》2025年第2期125-129,共5页Shandong Medical Journal

基　　金：山西省自然科学基金项目(202103021224004)。

摘　　要：神经调节蛋白1(NRG1)基因融合通过增强NRG1/ErbBs受体配体复合物的表达,激活PIK3-AKT/ERK等下游信号通路,对肿瘤的形成和发展起到重要作用。NRG1基因融合可能通过持续激活生长信号通路、影响细胞黏附和迁移、促进血管生成及增强免疫逃逸等多种机制,促进非小细胞肺癌(NSCLC)的发生发展。研究显示,NRG1基因融合在NSCLC中的发生率相对较低,更常见于不吸烟的女性肺腺癌患者,其中CD74-NRG1、SLC3A2-NRG1、SDC4-NRG1等是较为常见的融合类型。这些患者通常预后不佳,生存期显著缩短。NRG1基因融合的NSCLC患者对标准化疗和免疫治疗的反应不佳。已有研究表明,阿法替尼、Zenocutuzumab及靶向ErbB3的单克隆抗体能够显著提高患者的客观反应率和无进展生存期,为NRG1基因融合NSCLC的治疗带来了希望。Through the activation of downstream signaling pathways such PIK3-AKT/ERK and the enhancement of NRG1/ErbBs receptor ligand complex expression,neuroregulin 1(NRG1)gene fusion plays a significant role in the tumor formation and development.By altering cell adhesion and migration,boosting angiogenesis,improving immune evasion,and continuously activating growth signaling pathways,NRG1 gene fusion may contribute to the development of non-smallcell lung cancer(NSCLC).According to studies,NRG1 gene fusion has a comparatively low prevalence in NSCLC,and is more prevalent in female non-smoking individuals with lung adenocarcinoma.Common fusion types are CD74-NRG1,SLC3A2-NRG1,and SDC4-NRG1.These individuals typically have a bad prognosis,meaning their survival considerably decreased.Patients with NSCLC who have NRG1 gene fusion respond poorly to immunotherapy and conventional treat ment.Previous studies have shown that afatinib,Zenocutuzumab,and ERBB3-targeting monoclonal antibodies can signifi cantly improve the objective response rate and progression-free survival of patients,bringing hope for the treatment of NSCLC with NRG1 gene fusion.

关 键 词：神经调节蛋白1 非小细胞肺癌 NRG1基因融合 CD74-NRG1 SLC3A2-NRG1 SDC4-NRG1 

分 类 号：R734.2[医药卫生—肿瘤]